ServiceNow Inc vs Viatris Inc — how do they compare? ServiceNow Inc trades at $101.32 (market cap $107.98B), while Viatris Inc trades at $17.58 (market cap $19.79B). The key difference: ServiceNow Inc is far larger — about 5.5× Viatris Inc's market cap, and Viatris Inc pays a 2.83% dividend while ServiceNow Inc pays none. Which is the better fit depends on your goals.
| NOW | VTRS | |
|---|---|---|
Market Cap | $107.98B | $19.79B |
Sector | Technology | Health |
52-Week High | $199.24 | $17.39 |
52-Week Low | $83.00 | $8.74 |
Enterprise Value | $105.23B | $32.00B |
Dividend Yield | — | 2.83% |
Signals from Pluang's Aura AI — not financial advice
ServiceNow (NOW) trades at $103.24, down 0.74% today, with a bearish technical signal but strong fundamentals including 76.56% gross margins and consistent revenue growth to $13.28B in 2025. The stock shows robust cash flow generation of $5.44B from operations and has beaten earnings estimates in three of the last four quarters. Recent news highlights AI-driven growth opportunities and conference presentations.
Outlook remains positive with an 85.51% analyst buy rating and $135.14 consensus price target, suggesting 31% upside. Key risks include high valuation multiples (P/E 62.32) and competitive pressures in enterprise software. Earnings execution and AI adoption present the primary catalysts for continued appreciation.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management (ITSM), expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service (PaaS).
Read more on NOW →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →